الفهرس 
obesityOnly 14 pages are availabe for public view
 |  | from | 188 |  |  |
| | | from | 188 | | |
Abstract
Objective: Potential benefits of combining docosahexaenoic acid (DHA), an omega-3 fatty acid with flurbiprofe
(Flu), a non-steroidal anti-inflammatory drug in ameliorating obesity remain to be elucidated. This study aimed
to investigate the possible protective effects of DHA and Flu, either alone or in combination, against obesity
induced
metaflammation and to clarify the underlying molecular mechanisms.
Methods: Seventy-five male Wistar rats were divided into five groups: normal diet (ND) group, high-carbohy
drate
high-fat
diet
(HCHFD)
control
group,
DHA
group
(HCHFD+200 mg/kg
DHA),
Flu
group
(HCHFD+10 mg/kg Flu), and DHA+Flu group (HCHFD+DHA+Flu). Treatments were administered orally
daily for 8 consecutive weeks, parallel with the start of diets.
Results: Plasma levels of glucose, insulin, and TGs were significantly reduced in DHA, Flu, and DHA+Flu
treated groups, while HDL-C concentrations were significantly elevated in the same groups, compared to HCHFD
control group. Only Flu and DHA+Flu groups showed a significant decrease in plasma levels of leptin, TC, and
LDL-C, relative to HCHFD control group. Concentrations of phosphorylated adenosine monophosphate-activated
protein kinase (pAMPK) and resolvin D1 (RvD1) in epididymal adipose tissue (EAT) were significantly increased
in the three treated groups, compared with HCHFD control group. Expression of AMPK
-
subunit in EAT was
.1
significantly increased, whereas expression of nuclear factor kappa B (NF-
.B)
was significantly decreased in EAT
of the three treated groups, relative to HCHFD control group.
Conclusions: Docosahexaenoic acid-flurbiprofen combination showed an ameliorative effect on obesity-asso
ciated
metaflammation and its consequences in rats. Objective: Potential benefits of combining docosahexaenoic acid (DHA), an omega-3 fatty acid with flurbiprofe
(Flu), a non-steroidal anti-inflammatory drug in ameliorating obesity remain to be elucidated. This study aimed
to investigate the possible protective effects of DHA and Flu, either alone or in combination, against obesity
induced
metaflammation and to clarify the underlying molecular mechanisms.
Methods: Seventy-five male Wistar rats were divided into five groups: normal diet (ND) group, high-carbohy
drate
high-fat
diet
(HCHFD)
control
group,
DHA
group
(HCHFD+200 mg/kg
DHA),
Flu
group
(HCHFD+10 mg/kg Flu), and DHA+Flu group (HCHFD+DHA+Flu). Treatments were administered orally
daily for 8 consecutive weeks, parallel with the start of diets.
Results: Plasma levels of glucose, insulin, and TGs were significantly reduced in DHA, Flu, and DHA+Flu
treated groups, while HDL-C concentrations were significantly elevated in the same groups, compared to HCHFD
control group. Only Flu and DHA+Flu groups showed a significant decrease in plasma levels of leptin, TC, and
LDL-C, relative to HCHFD control group. Concentrations of phosphorylated adenosine monophosphate-activated
protein kinase (pAMPK) and resolvin D1 (RvD1) in epididymal adipose tissue (EAT) were significantly increased
in the three treated groups, compared with HCHFD control group. Expression of AMPK
-
subunit in EAT was
.1
significantly increased, whereas expression of nuclear factor kappa B (NF-
.B)
was significantly decreased in EAT
of the three treated groups, relative to HCHFD control group.
Conclusions: Docosahexaenoic acid-flurbiprofen combination showed an ameliorative effect on obesity-asso
ciated
metaflammation and its consequences in rats.
vascularization which leads to areas with lower oxygen availability [6].
Furthermore, adipocytes undergo a profound change in their secretome
Obesity is a major health hazard marked by excessive body fat ac
profile by an increased expression of pro-inflammatory cytokines and
/m2.
cumulation
and elevated body mass index (BMI) that exceeds 30 kg
alterations in the level of adipokines [7]. These changes result in an
It is prevalently escalating with a present count of more than 500
undesirable inflammatory cells infiltration [8] associated with an in
million having a high risk of morbidity [1] and it is likely to double by
creased
necrosis of adipocytes [9].
2040 [2]. The most common cause of obesity was found to be a long
This chronic inflammation linked to metabolic cells (metaflamma
term
imbalance between energy intake and expenditure [3], which
tion)
is deleterious and leads to local WAT dysfunction and systemic
occurs primarily due to sedentary lifestyles and unhealthy dietary ha
metabolic complications including insulin resistance, type 2 diabetes,
bits,
specifically diets rich in saturated fats and carbohydrates [4].
dyslipidemia, etc. [10]. Monotherapies often offer small to moderate
White adipose tissue (WAT) plays a crucial endocrine role in bal
weight loss benefits, while polytherapies seem to show more promising
ancing
metabolic homeostasis and inflammation-modulatory activities
results in the management of obesity and related comorbidities [11].
beyond the paradigm of fuel storage [5]. During conditions of pro
Therefore, development of new therapeutic strategies is of vital im
longed
over-nutrition, there is an expansion of adipose tissue mass
portance
[12].
through hypertrophy and hyperplasia, causing a reduction in tissue
Flurbiprofen (Flu), a nonsteroidal anti-inflammatory drug (NSAID.